NP
NBIX icon

Nilsine Partners’s Neurocrine Biosciences NBIX Stock Holding History

Nilsine Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
10,013
+348
+4% +$51.6K 0.12% 172
2026
Q1 		$1.24M Buy
9,665
+1,228
+15% +$163K 0.1% 186
2025
Q4 		$1.2M Buy
+8,437
New +$1.22M 0.1% 190

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Nilsine Partners's NBIX Position: Q2 2026 in Review

Nilsine Partners increased its Neurocrine Biosciences (NBIX) stake by 3.6% in Q2 2026, buying an estimated $51.6K and bringing the position to 10,013 shares worth $1.69M. The position accounts for 0.12% of the portfolio, ranked #172.

Nilsine Partners first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Nilsine Partners held 10,013 shares of Neurocrine Biosciences worth $1.69M as of Q2 2026.
  • Nilsine Partners bought 348 Neurocrine Biosciences shares in Q2 2026, an estimated $51.6K.
  • Neurocrine Biosciences made up 0.12% of Nilsine Partners's portfolio in Q2 2026, its #172 holding.
  • Nilsine Partners first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.